CHRONIC HEPATITIS B

This study tests whether combining two drugs, VIR-2218 and peginterferon alfa-2a, can lower hepatitis B virus levels in people with mild or inactive chronic infection. About 50 adults aged 18 to 65 will receive monthly VIR-2218 shots for 6 months and weekly peginterferon shots fo…

This study tests whether adding a new drug called GST-HG141 (Neracorvir) to standard antiviral treatment can better control chronic hepatitis B in people whose current medication isn't working well enough. About 526 adults aged 18-70 who have been on antivirals for over a year wi…

This study tests whether tenofovir alafenamide (TAF) is safe and effective for children and teens with chronic hepatitis B. About 150 participants will receive either TAF or a placebo. The goal is to see if the drug can lower the virus in the blood and to find the right dose for …

This study looks at whether adding a specific gut bacteria (Bacteroides fragilis) and branched-chain amino acids to standard hepatitis B treatment can help clear the virus. About 40 adults with chronic hepatitis B will take the combo alongside their usual antiviral drugs, and the…

This study tests whether dapagliflozin, a diabetes medication, can prevent serious liver complications like liver cancer or liver failure in people with chronic hepatitis B and diabetes. About 412 participants will take either the drug or a placebo daily for up to 5 years. The go…

This early-stage study tests the safety of a new drug, Tune-401, in 36 adults with chronic hepatitis B. Participants must already be on standard antiviral therapy. The main goal is to see if the drug is safe and how the body processes it. This is not a cure, but a step toward bet…

This study looks at how the drug TAF works in pregnant women with chronic hepatitis B. The goal is to see if it safely lowers the virus and prevents passing it to the baby. About 50 women will take TAF during late pregnancy, and their infants will be tested for the virus between …

This study tests whether a mobile app called HBVCare can help people with chronic hepatitis B take their medication regularly and attend follow-up visits. About 70 adults in Vietnam will either use the app or receive standard care. After three months, researchers will compare how…

This study tests a drug called Imdusiran (AB-729) in 10 adults with chronic hepatitis B. Participants get 4 injections over 8 months and have two liver biopsies to measure how the drug works inside the liver and how it affects the virus. The goal is to understand the drug's actio…

This study tests a new combination of drugs to help people with chronic hepatitis B achieve a 'functional cure'—meaning the virus is no longer active in the body. About 120 adults aged 18-70 will receive an immune-boosting drug (anti-PD-1 antibody) along with standard antivirals.…

This study tests an experimental injection called HRS-5635, given alone or with other drugs, in 369 adults with chronic hepatitis B. Participants must already be on standard antiviral pills with undetectable virus levels. The main goal is to see if the treatment can lower or clea…

This study tests azvudine tablets in 120 adults with chronic hepatitis B to see if the drug can control the virus long-term. The approach combines antiviral action with immune system activation. Participants take the medication daily for 12 months, and researchers monitor viral l…

This early-stage study is testing whether HEPLISAV-B, a vaccine normally used to prevent hepatitis B, is safe for people who already have chronic hepatitis B. Ten adults on antiviral therapy will receive two vaccine shots and be monitored for side effects and immune responses ove…

This study involves 16,300 people with chronic hepatitis B across three hospitals. The goal is to increase the number of patients referred to liver specialists and started on antiviral treatment. Researchers will also track how antiviral therapy affects patients' quality of life …

This study tests an experimental injection called AHB-137 in 60 adults with chronic hepatitis B who have already been treated with standard antiviral pills. The goal is to see if the injection can keep the virus undetectable in the blood even after stopping all hepatitis B medica…

This study follows 200 people with chronic hepatitis B who previously responded to the drug AHB-137. Researchers want to see if the virus stays suppressed over time without needing more treatment. Participants will have regular blood tests to monitor hepatitis B levels and liver …

This study tests a new two-drug combination (ASC22 and Peg-IFNa) to see if it can functionally cure chronic hepatitis B. It involves 150 adults with low virus levels who are not on other treatments. The goal is to raise the cure rate above 50% without needing lifelong medication.

This early-stage study tests a new medicine called SA1211, given as a shot under the skin. It first checks safety in healthy volunteers, then looks at how well it works in people with chronic hepatitis B. The goal is to see if the drug can help control the virus. About 80 people …

This study tests a new combination of drugs (an immune checkpoint inhibitor and interferon) to help the body clear the hepatitis B virus. The goal is to achieve a functional cure, meaning the virus is controlled without lifelong medication. About 120 adults with chronic hepatitis…

This study looks at whether magnetic resonance elastography (MRE), a special type of MRI, can accurately measure liver scarring (fibrosis) in people with chronic hepatitis B. Researchers will compare MRE results to standard liver biopsies in 600 adults. If successful, MRE could o…

This study follows 33,000 adults with chronic hepatitis B to see how different antiviral medicines affect their long-term health. Researchers will compare treatments to find which ones best prevent liver cancer and other serious liver problems. Participants continue their normal …

This study will follow 15,000 adults with chronic hepatitis B across 200 hospitals in China. Researchers will look at how different treatments affect liver cancer rates and other health outcomes. The goal is to find the best ways to manage the disease and work toward a cure.

This study looks at whether people with chronic hepatitis B who have undetectable virus levels in their blood also have undetectable virus in other body fluids like saliva or semen. Researchers will compare treated patients with suppressed virus and untreated patients with active…

This study looks at why the hepatitis B virus (HBV) stays in the liver for so long, even with treatment. Researchers will use a thin needle to take small samples from the liver of 100 adults with chronic HBV. They want to see how the virus and the body's immune cells interact, wh…